editorial

Rezūme: The Office-based Procedure in Benign Prostate Hyperplasia

Usama Nihad Rifat*

Emeritus Professor of Urology, The Iraqi Board of Medical Specializations

*Corresponding author: Usama Nihad Rifat, Emeritus Professor of Urology, The Iraqi Board of Medical Specializations

Received Date: 11 February, 2022

Accepted Date: 13 February 2023

Published Date: 15 February 2023

Citation: Rifat UN (2023) Rezūme: The Office-based Procedure in Benign Prostate Hyperplasia. J Urol Ren Dis 08: 1305. DOI: https://doi.org/10.29011/2575-7903.001305.

Edtorial

Benign Prostatic Hyperplasia (BPH) presents when the enlarged prostate squeezes the prostatic urethra, causing bladder outlet obstruction [1]. Minimally invasive surgical treatments help in symptom improvement. (Rezūme System, NxThera Inc., Maple Grove, MN, USA) is an example. It offers effective treatment of BPH, reduces sexual side effects, anesthetic requirements, and long hospitalizations.  Rezūme uses heated steam injections within the prostatic transition zone to thermally vaporize hyperplastic tissue. Studies showed the median operative time was 10.5 min. All patients were discharged few hours after surgery with indwelling urinary catheter that was removed after a median of 7 days. [2] It was also found that Rezūme is effective in patients with glands >80 cc [3]. Rezūm assures a short recovery time and return to normal activity and preserves sexual and ejaculatory functions [4]. Compared to aqua ablation they both use water, but in different ways. Rezūme is office-based and aqua ablation is operatingroom-based. One is minimally invasive, and the other is more a surgical management of BPH [5,6].

Exime® catheter (Rocamed; Munich, Germany). This catheter allows the patient to live a normal life without using any urine bag or catheter stopper. Indeed, Exime® (Rocamed) is a temporary prostatic stent which is inserted in the prostatic urethra, proximal to the sphincter, to enable the patient to urinate independently. This catheter was used instead of the standard catheter and patients started to urinate in a normal way immediately after the water vapor treatment. The treatment was performed as an outpatient procedure. Cases with a prostate volume of 186 cc. were managed successfully [7,8]. These initial data for the Rezūm System seem very promising. Rezūm has demonstrated significant improvements in American Urological Association symptom score, flow rate, and prostate volume reduction. When compared indirectly with medical therapy, Rezūm was superior to monotherapy. The Rezūm System has the advantage of being performed in an office setting under local anesthesia in prostates of various shapes and sizes. The Rezūm System also allows the treatment of median lobes while preserving erectile and ejaculatory function [9,10].

References

  1. Theodoros Spinos, Ioannis Katafigiotis, Ioannis Leotsakos, Nikolaos Grivas, et al. (2022) Rezūm water vapor therapy for the treatment of patients with urinary retention and permanent catheter dependence secondary to benign prostate hyperplasia: a systematic review of the literature, World J Urol 2022.
  2. Giampaolo Siena, L. Cindolo, G. Ferrari, D. Maruzzi, et al. (2021) Water vapor therapy(Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study. World Journal of Urology 39: 3875-3880.
  3. Raevti Bole, Ajay Gopalakrishna, Ruby Kuang, Jamal Alamiri, et al. (2020) Comparative Postoperative Outcomes of Rezūm Prostate, Ablation in   Patient with Large Versus Small Glands. JOURNAL OF ENDOUROLOGY 34: 778-781.
  4. Rodrigo Suarez-Ibarrola, Arkadiusz Miernik, Christian Gratzke, Dominik S. Schoeb (2021) Reasons for new MIS. Let’s be fair: iTIND, Urolift and Rezūm, World Journal of Urology 39: 2315-2327.
  5. Rowaiee R, Akhras A, Lakshmanan J, et al. (2021) (September 18, 2021) Rezum Therapy for Benign Prostatic Hyperplasia: Dubai’s Initial Cureus 13: e18083.
  6. Luca CINDOLO, Riccardo FERRARI, Salvatore RABITO, Giampaolo SIENA, et al. (2021) Rezūm procedure with Exime® stent: a step forward to micro-invasiveness, Minerva Urology and Nephrology 73: 273-275.   
  7. Rashed Rowaiee, Aya Akhras, Farhad Kheradmand Janahi (2021) Rezūm therapy, a feasible and safe treatment for the larger prostate.
  8. Dominique Guelce, Dominique Thomas, Dean Elterman (2018) Bilal Chughtai Recent advances in managing benign prostatic hyperplasia: The Rezūm System, F1000Research 2018.
  9. Andrea Cocci, Alessia Celeste Bocchino, Gianmartin Cito, Antonello De Lisa (2020) Role of Rezūm in the treatment of benign prostate hyperplasia: A review of the literature, Turk J Urol 47: 452-460.
  10. Enrico Checcucci, Alessandro Veccia, Sabrina De Cillis, Federico Piramide, et al. (2021) New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: A Systematic Review and Analysis of Comparative Outcomes, European Urology Open Science 33: 28-41.

 

© by the Authors & Gavin Publishers. This is an Open Access Journal Article Published Under Attribution-Share Alike CC BY-SA: Creative Commons Attribution-Share Alike 4.0 International License. With this license, readers can share, distribute, download, even commercially, as long as the original source is properly cited. Read More.

Journal of Urology and Renal Diseases